Below are current clinical trials.5 studies in Chronic myelogenous leukemia
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
This study is being done to store blood, buccal (cheek) cells, genetic material including DNA (deoxyribonucleic acid) and RNA (ribonucleic acid), and bone marrow so that they can be used for laboratory studies that may contribute to finding the causes of disease and factors that may determine disease progression and treatment response.
The purpose of this study is to determine the side effects of treatment with Nivolumab by itself or in combination in patients with relapsed/ refractory lymphoma or multiple myeloma.
The current study is a minimal risk study that involves abstraction of clinical and laboratory information from patients with myeloid disorders with the intent to accurately define the natural history of a specific disease. The information includes survival, cause of death, disease complications, treatment, and other issues.
May 26, 2016
- Chronic myelogenous leukemia. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Dec. 22, 2015.
- Chronic myelogenous leukemia treatment (PDQ). National Cancer Institute. http://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq. Accessed Jan. 3, 2016.
- Lichtman MA, et al. Chronic myelogenous leukemia and related disorders. In: Williams Hematology. 8th ed. New York, N.Y.: The McGraw-Hill Companies; 2010. http://accessmedicine.mhmedical.com/content.aspx?bookid=358§ionid=39835912. Accessed Jan. 3, 2016.
- Niederhuber JE, et al. eds. Chronic myeloid leukemia. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://clinicalkey.com. Accessed Dec. 22, 2015.
- Integrative medicine and complementary and alternative therapies as part of blood cancer care. The Leukemia & Lymphoma Society. http://www.lls.org/sites/default/files/file_assets/integrativemedicinecamtherapies.pdf. Accessed Jan. 3, 2016.
- When cancer doesn't go away. American Cancer Society. http://www.cancer.org/treatment/survivorshipduringandaftertreatment/when-cancer-doesnt-go-away. Accessed Jan. 3, 2016.
- About us. Mayo Medical Laboratories. http://www.mayomedicallaboratories.com/about/index.html. Accessed Jan. 3, 2016.
- AskMayoExpert. Chronic myelogenous leukemia. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Van Etten RA. Clinical manifestations and diagnosis of chronic myeloid leukemia. http://www.uptodate.com/home. Accessed Jan. 13, 2016.
- Negrin RS, et al. Overview of the treatment of chronic myeloid leukemia. http://www.uptodate.com/home. Accessed Jan. 13, 2016.
Chronic myelogenous leukemia